1083100-27-9

Basic information

• Product Name: N-[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl Lansoprazole Sulfide
• Synonyms: N-[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl Lansoprazole Sulfide;Lansoprazole related substance;1-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]thio]-1H-benziMidazole;Lansoprazole Related Compound 3;Lansoprazole Impurity 1;1-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)-2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)THIO)-1H-BENZO[D]IMIDAZOLE
• CAS NO: 1083100-27-9
• Molecular Formula: C25H22F6N4O2S
• Molecular Weight: 556.5231992
• Product Categories: Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Impurity
• Mol File: 1083100-27-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 622.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 5.25±0.30(Predicted)
• CAS DataBase Reference: N-[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl Lansoprazole Sulfide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl Lansoprazole Sulfide(1083100-27-9)
• EPA Substance Registry System: N-[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl Lansoprazole Sulfide(1083100-27-9)

Safety Data

• Hazardous Substances Data: 1083100-27-9(Hazardous Substances Data)

Upstream product

• 134469-07-1 Benzimidazol-2-thiol 

Downstream Products

• 1083100-26-8 1-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole 

Relevant articles and documents

Synthesis and characterization of metabolites and potential impurities of lansoprazole, an antiulcerative drug

Lansoprazole (Prevacid) is an antiulcerative drug used for the treatment of duodenal and gastric ulcers, reflux oesophagitis, and Zollinger-Ellison syndrome. During the bulk synthesis of lansoprazole, we have observed five impurities: lansoprazole N-oxide, lansoprazole sulfone N-oxide, lansoprazole sulfide, lansoprazole sulfone and N-aralkyl lansoprazole. The present work describes the synthesis and characterization of these impurities. Copyright Taylor & Francis Group, LLC.